PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity

被引:29
作者
Daenthanasanmak, Anusara [1 ]
Wu, Yongxia [1 ]
Iamsawat, Supinya [1 ]
Nguyen, Hung D. [1 ]
Bastian, David [1 ]
Zhang, MengMeng [1 ]
Sofi, M. Hanief [1 ]
Chatterjee, Shilpak [2 ]
Hill, Elizabeth G. [3 ]
Mehrotra, Shikhar [2 ]
Kraft, Andrew S. [4 ]
Yu, Xue-Zhong [1 ,5 ]
机构
[1] Med Univ South Carolina, Hollings Canc Ctr, Dept Microbiol & Immunol, Charleston, SC 29425 USA
[2] Med Univ South Carolina, Hollings Canc Ctr, Dept Surg, Charleston, SC 29425 USA
[3] Med Univ South Carolina, Hollings Canc Ctr, Dept Publ Hlth Sci, Charleston, SC 29425 USA
[4] Univ Arizona, Ctr Canc, Tucson, AZ USA
[5] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA
关键词
VERSUS-HOST-DISEASE; PROSTATE-CANCER CELLS; HUMAN DENDRITIC CELLS; SERINE/THREONINE KINASES; MULTIPLE-MYELOMA; BREAST-CANCER; ACUTE GVHD; IN-VIVO; GROWTH; SURVIVAL;
D O I
10.1172/JCI95407
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
PIM kinase family members play a crucial role in promoting cell survival and proliferation via phosphorylation of their target substrates. In this study, we investigated the role of the PIM kinases with respect to T cell responses in transplantation and tumor immunity. We found that the PIM-2 isoform negatively regulated T cell responses to alloantigen, in contrast to the PIM-1 and PIM-3 isoforms, which acted as positive regulators. T cells deficient in PIM-2 demonstrated increased T cell differentiation toward Th1 subset, proliferation, and migration to target organs after allogeneic bone marrow transplantation, resulting in dramatically accelerated graft-versus-host disease (GVHD) severity. Restoration of PIM-2 expression markedly attenuated the pathogenicity of PIM-2-deficient T cells to induce GVHD. On the other hand, mice deficient in PIM-2 readily rejected syngeneic tumor, which was primarily dependent on CD8(+) T cells. Furthermore, silencing PIM-2 in polyclonal or antigen-specific CD8(+) T cells substantially enhanced their antitumor response in adoptive T cell immunotherapy. We conclude that PIM-2 kinase plays a prominent role in suppressing T cell responses, and provide a strong rationale to target PIM-2 for cancer immunotherapy.
引用
收藏
页码:2787 / 2801
页数:15
相关论文
共 66 条
[1]   Prevention of lethal acute GVHD with an agorfistic CD28 antibody and rapamycin [J].
Albert, MH ;
Yu, XZ ;
Martin, PJ ;
Anasetti, C .
BLOOD, 2005, 105 (03) :1355-1361
[2]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[3]   Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells [J].
An, Ningfei ;
Lin, Ying-Wei ;
Mahajan, Sandeep ;
Kellner, Joshua N. ;
Wang, Yong ;
Li, Zihai ;
Kraft, Andrew S. ;
Kang, Yubin .
STEM CELLS, 2013, 31 (06) :1202-1212
[4]   Memory CD4+ T cells do not induce graft-versus-host disease [J].
Anderson, BE ;
McNiff, J ;
Yan, J ;
Doyle, H ;
Mamula, M ;
Shlomchik, MJ ;
Shlomchik, WD .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (01) :101-108
[5]   Chimeric Antigen Receptor Therapy for Cancer [J].
Barrett, David M. ;
Singh, Nathan ;
Porter, David L. ;
Grupp, Stephan A. ;
June, Carl H. .
ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 :333-347
[6]   The human Pim-2 proto-oncogene and its testicular expression [J].
Baytel, D ;
Shalom, S ;
Madgar, I ;
Weissenberg, R ;
Don, J .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1442 (2-3) :274-285
[7]   Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells [J].
Beharry, Zanna ;
Zemskova, Marina ;
Mahajan, Sandeep ;
Zhang, Fengxue ;
Ma, Jian ;
Xia, Zuping ;
Lilly, Michael ;
Smith, Charles D. ;
Kraft, Andrew S. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (06) :1473-1483
[8]   Crystal Structure of the PIM2 Kinase in Complex with an Organoruthenium Inhibitor [J].
Bullock, Alex N. ;
Russo, Santina ;
Amos, Ann ;
Pagano, Nicholas ;
Bregman, Howard ;
Debreczeni, Judit E. ;
Lee, Wen Hwa ;
von Delft, Frank ;
Meggers, Eric ;
Knapp, Stefan .
PLOS ONE, 2009, 4 (10)
[9]   The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases [J].
Caldwell, SA ;
Ryan, MH ;
McDuffie, E ;
Abrams, SI .
JOURNAL OF IMMUNOLOGY, 2003, 171 (05) :2402-2412
[10]   Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future [J].
Chen, Lieping ;
Han, Xue .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) :3384-3391